![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
February 9, 2024
In January, the medical community lost an acclaimed oncology physician, researcher, teacher, and health equity pioneer
February 9, 2024
This phase 2 trial is evaluating the combination of two different types of targeted drugs—sotorasib and panitumumab—that appear to be synergistic
February 9, 2024
Colleagues at ThedaCare and the Metro-Minnesota Community Oncology Research Consortium share their perspectives on facilitating just-in-time access to NCTN therapeutic trials
February 9, 2024
Amidst a persistent drug shortage, the BRIDGE trial seeks another possible first-line treatment option for patients
February 9, 2024
A member of ECOG-ACRIN since 2014
February 9, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
December 19, 2023
The co-chairs reflect on the year's key accomplishments and look ahead to 2024
December 19, 2023
In November, the cancer research community lost a trailblazer in cancer research and community oncology who was a national champion for diversity
December 19, 2023
This randomized phase 3 trial is testing whether second-line treatment with hepatic arterial infusion and systemic chemotherapy is more effective than systemic chemotherapy alone
December 19, 2023
The Fall 2023 Group Meeting was notable for a prominent increase in attention to diversity, equity, and inclusion
December 19, 2023
Elevating the role of APPs as partners in the clinic will help to reinforce the important role clinical trials play in cancer care and strengthen accrual efforts
December 19, 2023
In an annual evaluation, 46 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research